微信关注
Total item
Cart Subtotal
￥ 0.00 Angiogenesis
Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.
-
A 77-01
Catalog No. A14436 -
LDK378 (Ceritinib) dihydrochloride
Catalog No. A15142 ALK 抑制剂LDK378 (Ceritinib) dihydrochloride是有效的抗ALK抑制剂，IC50为0.2 nM，对IGF-1R和InsR的选择性分别为40倍和35倍。 了解更多 -
Entrectinib
Catalog No. A15801 TRK, ROS1, ALK 抑制剂Entrectinib，也称为RXDX-101和NMS-E628，是TrkA，TrkB和TrkC以及ROS1和ALK的小分子抑制剂，具有很高的效力和选择性。 了解更多 -
Brigatinib (AP26113)
Catalog No. A13450 ALK 抑制剂Brigatinib (AP26113)是一种有效的选择性ALK（IC50，0.6 nM）和ROS1（IC50，0.9 nM）抑制剂。它还以较低的效力抑制ROS1，FLT3和FLT3（D835Y）和EGFR的突变体。 了解更多 -
LDN-214117
Catalog No. A16096 -
Alectinib Hydrochloride
Catalog No. A18000 ALK inhibitorAlectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. 了解更多 -
Belizatinib
Catalog No. A20919 ALK/TRKA/TRKB/TRKC inhibitorBelizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7?nM for wild-type recombinant ALK kinase. 了解更多 -
Ensartinib hydrochloride
Catalog No. A21719 ALK/MET inhibitorEnsartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. 了解更多 -
Olmutinib (HM61713)
Catalog No. A15976 -
Btk inhibitor 1
Catalog No. A16260 -
LFM-A13
Catalog No. A16261 -
PCI 29732
Catalog No. A16262 -
Poseltinib (HM71224, LY3337641)
Catalog No. A19450 BTK inhibitorPoseltinib, an orally active, selective and irreversible Bruton??s tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. 了解更多 -
CHMFL-BTK-01
Catalog No. A12538 BTK inhibitorCHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. 了解更多 -
Ibrutinib Racemate
Catalog No. A18022 Btk inhibitorIbrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. 了解更多 -
(R)-Zanubrutinib
Catalog No. A21342 BTK inhibitor(R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. 了解更多 -
Btk inhibitor 1 (R enantiomer)
Catalog No. A21861 BTK inhibitorBtk inhibitor 1 R enantiomer (Ibrutinib analog) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
Btk inhibitor 1 R enantiomer hydrochloride
Catalog No. A21865 BTK inhibitorBtk inhibitor 1 R enantiomer hydrochloride (Ibrutinib analog hydrochloride) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
GDC-0834
Catalog No. A21243 -
Tirabrutinib
Catalog No. A21019 BTK inhibitorTirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with an IC50 of 2.2 nM. 了解更多 -
PCI-32765 (Ibrutinib)
Catalog No. A11020 Bruton tyrosine kinase 抑制剂PCI-32765 (Ibrutinib)是Bruton酪氨酸激酶（BTK）的口服生物利用小分子抑制剂，具有潜在的抗肿瘤活性。对Bmx，CSK，FGR，BRK及HCK适度有效，对EGFR，Yes，ErbB2，JAK3等作用效果较弱。 了解更多 -
CGI1746
Catalog No. A11348 -
GDC-0834 Racemate
Catalog No. A12706 -
AVL-292 benzenesulfonate
Catalog No. A15008 BTK 抑制剂AVL-292 benzenesulfonate是一种共价，高选择性，口服活性的Btk小分子抑制剂，IC50值为0.5 nM，选择性是其他测定激酶的1400倍以上。 了解更多 -
ACP-196 (Acalabrutinib)
Catalog No. A15824 Btk 抑制剂ACP-196是Bruton酪氨酸激酶（BTK）抑制剂，具有潜在的抗肿瘤活性。它抑制BTK的活性并阻止B细胞抗原受体（BCR）信号传导途径的激活。 了解更多 -
BMS-935177
Catalog No. A16905 -
Vecabrutinib
Catalog No. A17189 -
PF-06250112
Catalog No. A18612 BTK 抑制剂PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. 了解更多 -
PF-04554878 (Defactinib)
Catalog No. A11929 FAK 抑制剂PF-04554878 (Defactinib)是一种新型FAK激酶抑制剂，可降低胰腺神经内分泌肿瘤细胞的生长并诱导其凋亡。 了解更多 -
NVP-TAE 226
Catalog No. A11507 FAK 抑制剂NVP-TAE 226是一种强效FAK抑制剂，IC50为5.5 nM，对pyk2(IC50=3.5 nM)有适度的强效作用；对InsR, IGF-1R, ALK和c-Met的效力降低10-100倍。 了解更多
FILTER BY:
Filtering:
- 作用机制: Inhibitor (抑制剂) 删除该内容
购物选项
- 分类
- 靶点
-
- Abl (6)
- ALK (1)
- Aurora A (8)
- Aurora B (4)
- Aurora C (1)
- Axl (1)
- B-Raf (3)
- Bcr-Abl (1)
- C-Raf (Raf-1) (3)
- CDK (2)
- CDK2 (2)
- CDK4 (1)
- Chk2 (1)
- CSF1R (5)
- EGFR (23)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- EphB4 (2)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FAK (10)
- FGFR (2)
- FGFR1 (23)
- FGFR2 (11)
- FGFR3 (12)
- FGFR4 (9)
- FLT3 (28)
- HDAC (1)
- HER2 (2)
- IGF1R (1)
- JAK1 (1)
- JAK2 (9)
- JAK3 (3)
- Kit (14)
- Lck (1)
- Lyn (1)
- Mer (1)
- PDGFR (1)
- PDGFRα (10)
- PDGFRβ (18)
- PKCα (1)
- PKCβ (1)
- PYK2 (4)
- RET (6)
- Src (5)
- STAT1 (1)
- Syk (2)
- TrkA (2)
- VEGFR1 (FLT1) (12)
- VEGFR2 (FLK1) (25)
- VEGFR3 (FLT4) (11)
ADOOQ 产品质量保证
We promise all products to perform as described.